GLP-3R and Retatrutide: What the Human Trials Tell Us

What happens when one peptide is designed to activate three hormone receptors? That’s the idea behind retatrutide, which researchers have tested in randomized trials. If you’ve seen “GLP-3R” on a research-product listing, you may have found your way to this question already. Some listings use that label for a product described as retatrutide. The name to look for in clinical papers is retatrutide, sometimes called LY3437943. The label alone doesn’t tell you whether a product matches the formulation used in a trial. 1

What does “triple” mean?

Retatrutide is designed to activate receptors for three hormones: GIP, GLP-1, and glucagon. “Agonist” is the word for a molecule that activates a receptor. These pathways are of interest because they help regulate metabolism. Studying all three with one molecule lets researchers ask what that specific design does in people, including which benefits and side effects show up together. 1

What did human trials find?

In a phase 2 trial published in 2023, adults with obesity or with overweight and a weight-related condition were randomly assigned to retatrutide or placebo. People in the retatrutide groups lost more weight on average. Digestive side effects were common and researchers also observed increases in heart rate that peaked partway through the study and declined afterward. 1

TRIUMPH-2, a larger phase 3 trial led by researchers including a team in Seville, Spain, asked how retatrutide performed in adults who had both obesity and type 2 diabetes. At 80 weeks, mean weight loss across retatrutide groups ranged from 11.9% to 18.8%, compared with 5.1% in the placebo group, in the analysis that estimated results regardless of whether participants stayed on treatment. Researchers also tracked blood sugar and side effects, including nausea and diarrhea. 2

What makes those results useful?

You can see exactly who the study was designed for, what researchers compared, and how long they followed participants. That makes the findings more informative than a general headline about a “triple peptide.” It also gives you a way to read the next study: are researchers asking the same question, or looking at another group or outcome?

If you bring a paper to a conversation, note the full study name, who took part, and what outcome surprised you. How to Read a Peptide Study can help you make sense of the details. Peptide Education with Sarah is also a place to explore what a study found and think through questions for a licensed medical professional.